The activity of HH-GLI signalling observed in human cancer is the result of its functional interaction with other pathways and of the direct or indirect regulation of the final effectors of the HH signalling by oncogenes and tumour suppressors (Fig. 2). The gene discussed is GLI1; the disease is neoplasm.